Please login to the form below
Gyros Protein Technologies appoints chairman
Dr Frank Witney brings experience from Affymetrix and Dionex
Swedish Gyros Protein Technologies has appointed Dr Frank Witney as the new chairman of its board, succeeding David Patteson.
Dr Witney brings over 30 years of leadership experience in the life sciences industry, most recently having served as president and chief executive officer of Affymetrix.
He has held a number of executive roles in recent years, including serving as president and chief executive of both Dionex and Panomics, and was Packard Biosciences' chief operating officer before becoming president of life sciences after the firm's acquisition by Perkin Elmer.
Dan Calvo, Gyros Protein Technologies' chief executive, said: “We are delighted that Frank has joined as chairman.
“He brings with him a wealth of experience and knowledge in the field, and his guidance will be invaluable as we work to build Gyros Protein Tehcnologies following the merger earlier this year.”
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- Decision date for Sarepta’s Duchenne muscular dystrophy gene therapy delayed by FDA
- Seqera Labs and Genomics England partner to progress genomic research
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
- Survey launch: The future of HCP engagement impact
- Engaging with patients will create more effective patient pathways
- Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer
No results were found
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- ...
